Skip to content

EV / sales at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
6.3×+4.6×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
3.3×+0.6×
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
2.1×+0.4×
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
27.6×+3.1×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
9.4×+4.0×
LQD
Liquidia CorporationLQDA
10.8×-66.6×

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Calculated from Catalyst Pharmaceutical’s reported figures.

Based on the most recent quarter.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's EV / sales?
Catalyst Pharmaceutical (CPRX) reported EV / sales of 3.8× in Q1 2026.
How has Catalyst Pharmaceutical's EV / sales changed year-over-year?
Catalyst Pharmaceutical's EV / sales decreased by 14.1% year-over-year, from 4.4× to 3.8×.
What is the long-term trend for Catalyst Pharmaceutical's EV / sales?
Over 5 years (2020 to 2025), Catalyst Pharmaceutical's EV / sales has grown at a 15.3% compound annual growth rate (CAGR), from 1.8× to 3.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.